PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of canmedajCMAJ Information for AuthorsCMAJ Home Page
 
Can Med Assoc J. 1966 November 26; 95(22): 1120–1127.
PMCID: PMC1935821

The Treatment of Gout and Disorders of Uric Acid Metabolism with Allopurinol

Abstract

Allopurinol (4-hydroxypyrazolo (3,4-d)-pyrimidine) is a potent xanthine oxidase inhibitor which inhibits the oxidation of naturally occurring oxypurines, thus decreasing uric acid formation. The clinical and metabolic effects of this agent were studied in 80 subjects with primary and secondary gout and other disorders of uric acid metabolism. Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function. Oxypurine excretion increased concomitantly with the fall in urine uric acid. The agent is particularly valuable in the management of problems of gout with azotemia, acute uric acid nephropathy and uric acid urolithiasis. The minor side effects, clinical indications and theoretical complications are discussed.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page.

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association